New Therapeutic Options for Stroke Prevention in Atrial Fibrillation

Document Type


Presentation Date



This Forum presentation focuses on the clinical needs for the population at risk of strokes in atrial fibrillation (afib). For more than 50 years warfarin has stood alone as the gold standard therapy for the prevention of strokes in afib. Recently the FDA has approved three new Novel Oral AntiCoagulants (NOACs) to compete with warfarin. This session explores how these new therapies measure up: clinically, in the real world, and economically.
PowerPoint slides attached below. 45 slides. Presentation: 50 minutes

Jackson_ Forum Feb 13_JDC.pdf (1546 kB)
PowerPoint slides